NCT00202540

Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients

Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Institut de Recherches Internationales Servier · Academic / Other
• Sex: All
• Age: 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to demonstrate a long term efficacy of S18986 versus placebo on episodic memory performance in patients with MCI

Conditions

• Mild Cognitive Impairment

Interventions

Type	Name	Description
DRUG	S18986

Timeline

• Start date: 2005-06-01
• Primary completion: 2006-03-29
• Completion: 2006-03-29
• First posted: 2005-09-20
• Last updated: 2024-07-25

Locations

1 site across 1 country: France